Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Dose escalation
Gastrointestinal resections
Pazopanib
Therapeutic drug monitoring
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
05
06
2023
accepted:
01
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
aheadofprint
Résumé
Pazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and a narrow therapeutic index. To our knowledge, pazopanib exposure in patients with gastrointestinal resections (GIR) has not been described. This report focuses on feasibility of pharmacokinetics-guided dose escalation in these patients and clinical implications for their management. A retrospective data collection was performed for three patients with GIR treated with pazopanib, including pazopanib plasma concentrations (high-performance liquid chromatography with UV detection) and treatment adherence (Girerd score). First patient (55-year-old man, RCC, gastric bypass surgery) pazopanib C Optimal pazopanib exposure cannot be achieved in patients with GIR, and thus, other therapeutic strategies should be encouraged. Pretherapeutic assessment seems crucial to evaluate factors as bariatric surgery that may impact pazopanib concentrations. Therapeutic drug monitoring could be helpful to optimize pazopanib response in these patients.
Identifiants
pubmed: 37620675
doi: 10.1007/s00280-023-04574-z
pii: 10.1007/s00280-023-04574-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 28(6):1061–1068
doi: 10.1200/JCO.2009.23.9764
Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D et al (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111(10):1909–1916
doi: 10.1038/bjc.2014.503
pubmed: 25349968
pmcid: 4229638
Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N (2017) Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet sept 56(9):987–997
doi: 10.1007/s40262-017-0510-z
Yu H, van Erp N, Bins S, Mathijssen RHJ, Schellens JHM, Beijnen JH et al (2017) Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet mars 56(3):293–303
doi: 10.1007/s40262-016-0443-y
Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA et al (2019) The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET Study). Clin Pharmacol Ther 106(5):1076–1082
doi: 10.1002/cpt.1515
pubmed: 31125423
van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA (2014) Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol juill 15(8):e315-326
doi: 10.1016/S1470-2045(13)70579-5
Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N et al (2019) Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients. Clin Pharmacokinet 58(5):651–658
doi: 10.1007/s40262-018-0719-5
pubmed: 30367352
Noda S, Yoshida T, Hira D, Murai R, Tomita K, Tsuru T et al (2019) Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. Clin Genitourin Cancer avr 17(2):e306–e313
doi: 10.1016/j.clgc.2018.12.001
Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M et al (2017) Individualized pazopanib dosing-letter. Clin Cancer Res Off J Am Assoc Cancer Res. 23(20):6377
doi: 10.1158/1078-0432.CCR-17-1873
Minot-This MS, Boudou-Rouquette P, Jouinot A, de Percin S, Balakirouchenane D, Khoudour N et al (2022) Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients. Pharmaceutics 14(6):1224
doi: 10.3390/pharmaceutics14061224
pubmed: 35745797
pmcid: 9231369
Azran C, Wolk O, Zur M, Fine-Shamir N, Shaked G, Czeiger D et al (2016) Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev Off J Int Assoc Study Obes 17(11):1050–1066
doi: 10.1111/obr.12434
van Kinschot CMJ, van Erp NP, Feberwee T, Dezentjé VO (2015) Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery. Eur J Clin Pharmacol 71(10):1279–1281
doi: 10.1007/s00228-015-1902-3
pubmed: 26177716
de Wit D, van Erp NP, Khosravan R, Wiltshire R, Allred R, Demetri GD et al (2014) Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer 14(1):575
doi: 10.1186/1471-2407-14-575
pubmed: 25102852
pmcid: 4133599
Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol juill 9(7):629–635
doi: 10.1016/S1470-2045(08)70153-0
Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S (2001) Evaluation de l’observance du traitement antihypertenseur par un questionnaire: mise au point et utilisation dans un service spécialisé. Presse Méd 30(21):1044–1048
pubmed: 11471275
Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7(5):e37563
doi: 10.1371/journal.pone.0037563
pubmed: 22666367
pmcid: 3364283
Kessler ER, Hu J, Srivastava G, Kemme DJ, Iruku P, Rana V et al (2021) Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 39(15_Suppl):4544–4544
doi: 10.1200/JCO.2021.39.15_suppl.4544
Lubberman FJE, van der Graaf WTA, Xu L, Cleton A, Demetri GD, Gelderblom H et al (2019) The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. Br J Clin Pharmacol 85(10):2399–2404
doi: 10.1111/bcp.14061
pubmed: 31290566
pmcid: 6783594
van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT et al (2017) Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options. Clin Pharmacokinet 56(7):683–688
doi: 10.1007/s40262-016-0503-3
pubmed: 28101705
pmcid: 5488129
Krens SD, Lubberman FJE, van Egmond M, Jansman FGA, Burger DM, Hamberg P et al (2021) The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer 148(11):2799–2806
doi: 10.1002/ijc.33469
pubmed: 33428771
pmcid: 8048885